CHMP positive opinion for Bomyntra, and Conexxence biosimilars for the treatment of osteoporosis and other bone-related conditions – Fresenius Kabi
Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has issued a positive opinion for its denosumab biosimilar candidates, Bomyntra and Conexxence… read more.